The Prognosis and Predictive Value of Complement C3 in Patients with Multiple Myeloma / 中国实验血液学杂志

OBJECTIVE@#To investigate the effect of complement C3 on the prognosis of patients with multiple myeloma (MM), and to establish a predictive model to evaluate the overall survival.@*METHODS@#Eighty newly diagnosed MM patients were enrolled, and clinical characteristics, such as sex, age, platelet count, white blood cell count, ISS stage, FISH, levels of kappa and lammda chain, complement C3 and C4 were retrospectively analyzed. Cox regression model was used for univariate and multivariate analysis about risk factors that affecting the prognosis of the MM patients. A nomogram based on C3 level was established for predicting the prognosis of MM patients.@*RESULTS@#The average age of the MM patients was 63.15±10.41, including 36 males and 44 females. The median overall survival (OS) was 36.3 months, and the median progression-free survival (PFS) was 35.2 months, the 3-year OS rate and PFS rate of the MM patients were 67.5% and 52.5%, respectively. The variants selected by univariate analysis were put into multivariate regression model, the result showed that C3 level ≥0.7 U/L and PLT count <100×10@*CONCLUSION@#Patients with C3 level≥0.7 U/L or PLT count <100×10

Survival and Prognosis Analysis of 57 Patients with Multiple Myeloma / 中国实验血液学杂志

<p><b>OBJECTIVE</b>To investigate the relationship of clinical related indicator levels and clinical staging with the prognosis of MM patients so as to more accurately evaluate the disease status and guide the clinical treatment.</p><p><b>METHOD</b>The clinical indicators including age, WBC and Plt counts, FISH result, ISS staging, Kappa and Lammada light chain levels and so on in 57 cases of MM were analyzed retrospectively; the unvariate and multivatiate analyses of factors influencing the prognosis of MM patients were performed by Kaplan-Meier and Cox regression model; the factors influencing the prognosis of patients were evaluated.</p><p><b>RESULTS</b>Median age of 57 patients including 25 male and 32 female, was 63(29-81) years old, mean OS time was 37.3 months, mean PFS time was 36.3 months, 3-year OS and PFS were 73.6% and 56.1% respectively. The unvaviate analysis showed that age, WBC count, Plt count, FISH result, ISS staging, Kappa and lammda light chain levels, and remission were factors influencing the prognosis; the multivatiate analysis showed that the Kappa light chain level ≥19.4 mg/L and Plt count <100×10/L were independant risk factors influencing the prognosis of MM patients.</p><p><b>CONCLUSION</b>The prognosis of MM patients with high Kappa light chian level and low Plt count is very poor, therefore the therapeutic regimens should be selected differentially for this kind of newly diagnosed MM patients so as to enhance the survival time of patients.</p>

Therapeutic Efficacy of Multigly-Cosidorum Tripterygium Combined with rhIL-11 for Immune Thrombocytopenia / 中国实验血液学杂志

<p><b>OBJECTIVE</b>To study the therapeutic efficacy of multigly-cosidorum Tripterygium combined with rhIL-11 for treating patients with immune thrombocytopenia (ITP).</p><p><b>METHODS</b>A total of 75 patients with ITP were divided into 2 group: experimental group and control group. The experimental group included 40 patients who had been treated with multigly-cosidorum Tripterygium combined with rhIL-11. Multigly-cosidorum Tripterygium was given at a dose of 1mg/kg·d for 2 months and rhIL-11 was injected at a dose of 16,000,000 units per day. Control group included 35 patients who had been treated with prednisone at a dose of 1 mg/kg·d. Platelet counts were performed every day before platelet counts >30 × 10⁹/L. Peripheral blood T cells were collected before and after treated for 2 months. The ratios of CD4⁺, CD8⁺ T cells in peripheral blood T cells were analyzed by flow cytometry.</p><p><b>RESULTS</b>Totally effective rate in experimental group was 77.5%. Totally effective rate in control group was 82.9%. Totally effective rate showed no statistical difference between these two groups (P > 0.05). The average time of platelet count 30 × 10⁹/L in experimental and control groups were 13.06 ± 6.10 days and 9.76 ± 5.71 days respectively; in experimental group, the ratio of CD4⁺ T cells in peripheral blood was 21.03% before treatment, then rised to 34.49% after treatment for 2 months (P < 0.01); The ratio of CD8⁺ T cells in peripheral blood was 26.35% before treatment, then decreased to 20.18% (P < 0.01). In control group, the ratio of CD4⁺ T cells was 22.30% before treatment, then rised to 25.11% after treatment for 2 months (P < 0.05); The ratio of CD8⁺ T cells in peripheral blood was 27.24% before treatment, then decreased to 21.35% (P < 0.01).</p><p><b>CONCLUSION</b>Multigly-cosidorum tripterygium can correct disorder of T lymphocytes, the combination of multigly-cosidorum triptergium and rhIL-11 can accelerate therapeutic efficacy for treating ITP and with less adverse reaction, so this combination may be effective and safe for treating patients with ITP.</p>

Expression of integrins in bone marrow mesenchymal stem cells derived from patients with chronic myeloid leukemia / 中国实验血液学杂志

The purpose of this study was to investigate the growth characteristics and the expression level of integrin mRNA of the cultured bone marrow mesenchymal stem cells (BMMSCs) from patients with chronic myeloid leukemia (CML) in myeloid crisis (MC), and explore the role of BMMSCs in pathogenesis of CML. Five CML patients were enrolled in experimental group, five healthy persons were used as control. BMMSCs were cultured in vitro. The morphology of BMMSCs was observed every day and the growth curve were portrayed, and the ability of cell proliferation were detected according to the daily results of cell counting. Total RNA was extracted from third and fourth passages of BMMSCs, The expression of integrins mRNA of BMMSCs were measured by real-time PCR. The results showed that the BMMSCs of experimental and control groups had no difference in growth characterisctics, but the expression of integrins mRNA of the BMMSCs was higher in CML patients than in normal control group (p < 0.05). It is concluded that the abnormally high expression of integrins of BMMSC from the CML patients take part in pathogenesis of CML.